title: Assessing dalfampridine efficacy in the physician's office.
abstract: Dalfampridine (extended release 4-aminopyridine) is shown in three recent randomised controlled trials to improve walking speed in people with multiple sclerosis; however, the trial literature makes it clear that dalfampridine is effective in only a subset of patients. For the neurologist working in an everyday physician's office, a key question arises: How to distinguish the few who experience a meaningful clinical benefit, from the many who do not? This question has not yet been adequately addressed in the available literature.
authors.affiliation: Department of Neurology, Imperial College Healthcare NHS Trust, London, UK.
authors.forename: J B
authors.initials: JB
authors.lastname: Raffel
authors.forename: O
authors.initials: O
authors.lastname: Malik
authors.forename: R S
authors.initials: RS
authors.lastname: Nicholas
mesh_terms: D015761:4-Aminopyridine / Q000627:therapeutic use*; D006801:Humans; D051346:Mobility Limitation; D009103:Multiple Sclerosis / Q000150:complications* / Q000188:drug therapy*; D010824:Physicians' Offices; D026902:Potassium Channel Blockers / Q000627:therapeutic use*; D016896:Treatment Outcome; D016138:Walking
chemical_list: D026902:Potassium Channel Blockers; D015761:4-Aminopyridine
keywords: 4-Aminopyridine; cost benefit analysis; multiple sclerosis; treatment outcome; walking speed